In the News

Maria Jasin, a member of the Sloan Kettering Institute’s Developmental Biology Program, discusses her research.

Learn some of the ways MSK is advancing care for people with neurofibromatosis.

Pediatric oncologist Julia Glade Bender talks about the challenges of treating rare childhood cancers and how personalized medicine is leading to better therapies for tumors that are especially hard to treat.

Find out what going to therapy is actually like from MSK postdoctoral fellow Kailey Roberts.

Surprise! It has to do with metabolism.

A new analysis of survival data for the randomized, phase III PACIFIC trial finds adding the immunotherapy cancer drug durvalumab to radiation and chemotherapy significantly decreased the recurrence of lung cancer both in the chest area and in distant sites outside the chest. The updated PACIFIC trial data will be presented at the 61st Annual Meeting of the American Society for Radiation Oncology (ASTRO), by Andreas Rimner, MD, radiation oncologist, Memorial Sloan Kettering Cancer Center.

An MSK study explains how the drug selinexor, which was recently approved to treat multiple myeloma and is being tested in many other tumor types, stops cancer.

Memorial Sloan Kettering hosted its 24th annual “Thrivers” celebration to honor the patients, staff, and caregivers of the MSK Bone Marrow Transplantation (BMT) Service.

Gerstner Sloan Kettering recognizes student research by annually awarding the Grayer Fellowships, the Olayan Fellowship, the Robert B. Catell Fellowship, the Palestin Fellowship, and the Geoffrey Beene Graduate Student Fellowships.

Selpercatinib (also known as LOXO-292) is a highly selective RET inhibitor with activity against diverse RET fusions, activating RET mutations and brain metastasis. Phase 1/2 data from the LIBRETTO-001 trial presented at the IASLC 2019 World Conference on Lung Cancer demonstrates selpercatinib’s marked antitumor activity in RET fusion-position non-small cell lung cancer (NSCLC) patients. These findings, presented by Alexander Drilon, MD, principal investigator and Research Director of Early Drug Development at Memorial Sloan Kettering Cancer Center, will form the basis of an US Food and Drug Administration new drug application submission.